Clinical Experience of Serious Infections Caused by Enterobacteriaceae Producing VIM-1 Metallo- -Lactamase in a Greek University Hospital
Open Access
- 15 March 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (6), 847-854
- https://doi.org/10.1086/528719
Abstract
Background. The dissemination of acquired metallo-β-lactamases (MBLs) in members of the family Enterobacteriaceae is regarded as an emerging clinical threat. The clinical characteristics and outcomes of 17 cases of infection due to MBL-producing isolates were analyzed. Methods. During a 3-year period, medical records for all patients with confirmed infection due to an MBL-producing strain belonging to the Enterobacteriaceae family were retrospectively analyzed. We screened for MBL production with the imipenem-ethylenediaminetetraacetic acid disk synergy test, and results were confirmed by polymerase chain reaction. Genetic relatedness between isolates was evaluated by repetitive extragenic palindromic polymerase chain reaction. Results. Fourteen cases of bacteremia and 3 cases of ventilator-associated pneumonia due to an MBL-producing isolate were studied. Most of the patients had previously been colonized with an MBL-producing organism, and almost 60% had been exposed to carbapenems before infection. The isolated pathogens (Klebsiella pneumoniae, 14 cases; and Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes, 1 case each) exhibited variable minimum inhibitor concentrations of carbapenems (1 to >32 µg/mL) and resistance to most other β-lactams. Tigecycline was active against all isolates, whereas colistin and gentamicin were active against 88% of them. Molecular studies confirmed the presence of a gene belonging to blaVIM-1 cluster in all isolates. Among the 12 K. pneumoniae isolates, which were subjected to molecular typing, 11 distinct clones were identified. Five cases (∼30%) occurred in patients who were already receiving carbapenem-containing treatment, and carbapenem treatment was considered to have failed. Twelve cases were treated with a colistin-containing regimen. The attributable mortality rate was 18.8%. Conclusions. MBL-producing Enterobacteriaceae can cause severe, often fatal infection in severely ill patients, irrespective of the MIC of carbapenems. Colonization with an MBL-producer is a preceding event, highlighting the importance of surveillance. Both infection control practices and antibiotic policies should be intensified to contain the spread of these problematic bacteria.Keywords
This publication has 26 references indexed in Scilit:
- Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-β-lactamase VIM-1 in GreeceJournal of Antimicrobial Chemotherapy, 2007
- Characterization of a new integron containing blaVIM-1 and aac(6′)-IIc in an Enterobacter cloacae clinical isolate from GreeceJournal of Antimicrobial Chemotherapy, 2005
- Metallo-β-Lactamases: the Quiet before the Storm?Clinical Microbiology Reviews, 2005
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- First identification of an Escherichia coli clinical isolate producing both metalloβ-lactamase VIM-2 and extended-spectrum β-lactamase IBC-1Clinical Microbiology & Infection, 2004
- Spread of blaVIM-1-producing e. coli in a university hospital in Greece. Genetic analysis of the integron carrying the blaVIM-1 metallo-β-lactamase geneDiagnostic Microbiology and Infectious Disease, 2004
- VIM-1 Metallo-β-Lactamase-Producing Klebsiella pneumoniae Strains in Greek HospitalsJournal of Clinical Microbiology, 2003
- Metallo-β-Lactamase VIM-2 in Clinical Isolates ofPseudomonas aeruginosafrom PortugalMicrobial Drug Resistance, 2002
- Cloning and Characterization of bla VIM , a New Integron-Borne Metallo-β-Lactamase Gene from a Pseudomonas aeruginosa Clinical IsolateAntimicrobial Agents and Chemotherapy, 1999
- APACHE IICritical Care Medicine, 1985